Covid-19 vaccination reduces risk of cardiac events

Covid-19 vaccination

Researchers have revealed that vaccination against Covid-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2. 

The conclusions are based on analysis of the most extensive datasets in the United States by a team from the Icahn School of Medicine at Mount Sinai. 

It is the first study to examine both full and partial vaccination and the link to major adverse cardiac events (MACE) in the United States, confirming similar analyses performed previously using the Korean Covid-19 registry.  

“We sought to clarify the impact of previous vaccination on cardiovascular events among people who develop COVID-19 and found that, particularly among those with comorbidities, such as previous MACE, type 2 diabetes, high cholesterol, liver disease, and obesity, there is an association with a lower risk of complications. While we cannot attribute causality, it is supportive evidence that vaccination may have beneficial effects on a variety of post-Covid-19 complications,” said senior author Girish N Nadkarni, Irene and Dr Arthur M Fishberg Professor of Medicine at Icahn Mount Sinai, Director of The Charles Bronfman Institute of Personalized Medicine, and System Chief, Division of Data Driven and Digital Medicine (D3M), Department of Medicine. 

Huge dataset 

Researchers used the National COVID Cohort Collaborative (N3C) database, the largest national comprehensive database on Covid-19. Since its inception in 2020, the N3C has continuously collected and harmonised data from electronic health records of institutions across the country.  

Included in this study were 1,934,294 patients, 217,843 of whom received mRNA vaccine formulations by Pfizer-BioNTech or Moderna or viral vector technology by Johnson & Johnson. Cox proportional hazards, a statistical technique, was implemented to assess vaccination association with MACE. 

“To our surprise, even partial vaccination was associated with lower risk of adverse cardiovascular events,” said first study author Joy Jiang, an MD/PhD candidate in the lab of Dr Nadkarni. “Given the magnitude of SARS-CoV-2 infection worldwide, we hope our findings could help improve vaccination rates, especially in individuals with coexisting conditions.” 

Further work will be necessary to elucidate the mechanisms involved and clarify the role of SARS-CoV-2 subtypes and reinfections in their relationship to the risk of MACE. 

The research letter, ‘Impact of Vaccination on Major Adverse Cardiovascular Events in Patients with COVID-19 Infection,’ was published in the Journal of the American College of Cardiology. 

The research will also be presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, LA, USA.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free